Wu Li, Wang Jishi, Li Yong, Zuo Li, Zhang Zhiming, Ouyang Jinlin, Fan Jianmin, Li Hang
aDepartment of Oncology, People's Hospital of Guizhou Province, Guiyang bDepartment of Haematology, Guiyang College of Medicine, Guiyang, People's Republic of China.
Anticancer Drugs. 2014 Aug;25(7):826-31. doi: 10.1097/CAD.0000000000000067.
Recurrent diffuse large B-cell lymphoma (DLBCL) presents a significant challenge in the clinic, which necessitates the development of alternative therapeutic regimens. Here, we quantified the growth inhibition rate of a panel of clinically approved anticancer drugs in a patient-derived DLBCL cell line that is resistant to doxorubicin, a central component of the standard of care R-CHOP. Our study indicates that this cell line is especially sensitive to two taxanes, docetaxel and paclitaxel. Furthermore, the effective dose of taxane can be lowered when it is combined with other anticancer drugs. Our study provides guidance for preclinical studies to test alternative regimens for recurrent DLBCL.
复发性弥漫性大B细胞淋巴瘤（DLBCL）在临床上构成了重大挑战，这就需要开发替代治疗方案。在此，我们在一种对多柔比星耐药的患者来源的DLBCL细胞系中，量化了一组临床批准的抗癌药物的生长抑制率，多柔比星是标准治疗方案R-CHOP的核心组成部分。我们的研究表明，该细胞系对两种紫杉烷类药物多西他赛和紫杉醇特别敏感。此外，当紫杉烷类药物与其他抗癌药物联合使用时，其有效剂量可以降低。我们的研究为复发性DLBCL替代方案的临床前研究提供了指导。
